Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation

NCT04511130 is registered in ClinicalTrials.gov with Marker Therapeutics, Inc. as lead sponsor.

NCT NCT04511130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Lead sponsor
Marker Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 14, 2020
Completion date
March 1, 2024
Enrollment
92 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, stem cell transplantation